Search

Micromet AG, a spin-off from the Institute for Immunology at Munich University, said it has agreed to grant four licenses of its single chain antibody technology to Abbott Laboratories, Alligator Bioscience AB, Haptogen Ltd. and an unnamed biopharmaceutical company, for the development of cancer treatments.

Lipoxen Plc, a drug spin-out company from the University of London's School of Pharmacy, said it has raised £3.78 million from a placing of 28 million shares for hiring news staff for preclinical trials to treat diabetes, Pneumococcal infections, and hepatitis C.

A new report from MIT suggests that universities should avoid concentrating too much on technology transfer.

As expected, the IPO markets in Europe made their strongest showing in several years in 2005 and have even topped the amount of money raised in the U.S., according to figures released today by PricewaterhouseCoopers in London.

A new report on the state of micromanufacturing around the world.

Forget stem cells, pharmacogenomics and the next big cure - Michael Kenward gazes into his prophecy book to see what the physical sciences have in store for us this year. Or maybe not.